Discovery and verification of panels of T-lymphocyte proteins as biomarkers of Parkinson's disease

Scientific Reports

Volumn 2, Issue , 2012, Pages

  Alberio, Tiziana ^a   Pippione, Agnese C ^a   Zibetti, Maurizio ^b   Olgiati, Simone ^a   Cecconi, Daniela ^c   Comi, Cristoforo ^d   Lopiano, Leonardo ^b   Fasano, Mauro ^a  

^a UNIVERSITY OF INSUBRIA   (Italy)

^b UNIVERSITY OF TURIN   (Italy)

^c UNIVERSITY OF VERONA   (Italy)

^d UNIVERSITY OF EASTERN PIEDMONT   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; FIBRINOGEN; ISOPROTEIN; PROTEOME; TRANSALDOLASE;

ARTICLE; CHEMISTRY; HUMAN; PARKINSON DISEASE; T LYMPHOCYTE; TWO DIMENSIONAL GEL ELECTROPHORESIS; WESTERN BLOTTING;

BIOLOGICAL MARKERS; BLOTTING, WESTERN; ELECTROPHORESIS, GEL, TWO-DIMENSIONAL; FIBRINOGEN; HUMANS; PARKINSON DISEASE; PROTEIN ISOFORMS; PROTEOME; T-LYMPHOCYTES; TRANSALDOLASE;

EID: 84871744980     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep00953     Document Type: Article

References (29)

1. Jankovic, J. Parkinson's disease: clinical features and diagnosis. JNeurolNeurosurg Psychiatry. 79, 368-376 (2008). (Pubitemid 351441488)
2. Shulman, J. M., De Jager, P. L. & Feany, M. B. Parkinson's disease: genetics and pathogenesis. Annu Rev Pathol. 6, 193-222 (2011).
3. Morgan, J. C., Mehta, S. H. & Sethi, K. D. Biomarkers in Parkinson's disease. Curr Neurol Neurosci Rep. 10, 423-430 (2010).
4. Alberio, T. & Fasano, M. Proteomics in Parkinson's disease: An unbiased approach towards peripheral biomarkers and new therapies. J Biotechnol. 156, 325-337 (2011).
5. Gerlach, M. et al. Biomarker candidates of neurodegeneration in Parkinson's disease for the evaluation of disease-modifying therapeutics. J Neural Transm. 119, 39-52 (2012).
6. Fasano, M., Alberio, T. & Lopiano, L. Peripheral biomarkers of Parkinson's disease as early reporters of central neurodegeneration. Biomark Med. 2, 465-478 (2008).
7. Alberio, T. et al. Proteomic characterization of Jurkat T leukemic cells after dopamine stimulation: A model of circulating dopamine-sensitive cells. Biochimie. 93, 892-898 (2011).
8. Pacheco, R., Prado, C. E., Barrientos, M. J. & Bernales, S. Role of dopamine in the physiology of T-cells and dendritic cells. J Neuroimmunol. 216, 8-19 (2009).
9. Besser, M. J., Ganor, Y. & Levite, M. Dopamine by itself activates either D2, D3 or D1/D5 dopaminergic receptors in normal human T-cells and triggers the selective secretion of either IL-10, TNF alpha or both. J Neuroimmunol. 169, 161-171 (2005). (Pubitemid 41528789)
10. Blandini, F. et al. Calcium homeostasis is dysregulated in parkinsonian patients with L-DOPA-induced dyskinesias. Clin Neuropharmacol. 32, 133-139 (2009).
11. Jacob, A. M. & Turck, C. W. Detection of post-translational modifications by fluorescent staining of two-dimensional gels. Methods Mol Biol. 446, 21-32 (2008).
12. Mila, S. et al. Lymphocyte proteomics of Parkinson's disease patients reveals cytoskeletal protein dysregulation and oxidative stress. Biomark Med. 3, 117-128 (2009).
13. Alberio, T. et al.Dopaminergic therapies modulate the T-cell proteome of patients with Parkinson's disease. IUBMB Life 64, 846-852 (2012).
14. Nyhlén, J., Constantinescu, R. & Zetterberg, H. Problems associated with fluid biomarkers for Parkinson's disease. Biomark Med. 4, 671-681 (2010).
15. Surinova, S. et al. On the development of plasma protein biomarkers. J Proteome Res. 10, 5-16 (2011).
16. Grünblatt, E. et al. Pilot study: peripheral biomarkers for diagnosing sporadic Parkinson's disease. J Neural Transm. 117, 1387-1393 (2010).
17. Mollenhauer, B. et al. alpha-Synuclein and tau concentrations in cerebrospinal fluid of patients presenting with parkinsonism: a cohort study. Lancet Neurol. 10, 230-340 (2011).
18. Bogdanov, M. et al. Metabolomic profiling to develop blood biomarkers for Parkinson's disease. Brain. 131, 389-396 (2008). (Pubitemid 351197614)
19. Lachaise, F. et al. Relationship between posttranslational modification of transaldolase and catalase deficiency in UV-sensitive repair-deficient xeroderma pigmentosum fibroblasts and SV40-transformed human cells. Free Radic Biol Med. 30, 1365-1373 (2001). (Pubitemid 32522951)
20. Samland, A. K. & Sprenger, G. A. Transaldolase: from biochemistry to human disease. Int J Biochem Cell Biol. 41, 1482-1494 (2009).
21. Calne, S. M. & Kumar, A. Young onset Parkinson's disease. Practical management of medical issues. Parkinsonism Relat Disord 14, 133-142 (2008). (Pubitemid 351726309)
22. Merola, A. et al. Subthalamic nucleus deep brain stimulation outcome in young onset Parkinson's disease: a role for age at disease onset? J Neurol Neurosurg Psychiatry. 83, 251-257 (2012).
23. Frasier, M., Chowdhury, S., Eberling, J. & Sherer, T. Biomarkers in Parkinson's disease: a funder's perspective. Biomark Med. 4, 723-729 (2010).
24. Litvan, I. et al. Task force appraisal of clinical diagnostic criteria for parkinsonian disorders. Mov. Disord. 18, 467-486 (2003). (Pubitemid 36656531)
25. Litvan, I. et al. Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome): report of the NINDS-SPSP international workshop. Neurology 47, 1-9 (1996). (Pubitemid 26243849)
26. Gilman, S. et al. Second consensus statement on the diagnosis of multiple system atrophy. Neurology 71, 670-676 (2008).
27. Albrecht, D., Kniemeyer, O., Brakhage, A. A. & Guthke, R. Missing values in gelbased proteomics. Proteomics. 10, 1202-1211 (2010).
28. McDonald, J. H. Handbook of Biological Statistics. 2nd ed. Baltimore: Sparky House Publishing; 2009.
29. R Development Core Team. R: A language and environment for statistical computing. Vienna: R Foundation for Statistical Computing; 2009.